Vaccine innovation to prevent disease

about vaxxilon
;

At Vaxxilon, our goal is to discover and develop innovative vaccines to prevent disease. Our corporate values, employees, and partners are essential to improving health and building a great company.

Vaxxilon Shares Transferred to Idorsia as part of the J&J Actelion Acquisition
June 16, 2017

Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015.

More News

VPM – 10th International VPM Days
TWINCORE in Hannover, Germany | September 14, 2017

10th International VPM Days “15 Years VPM – from Target to Market” to be held on September 14 – 15, 2017 at the TWINCORE in Hannover, Germany

More Events

Semisynthetic glycoconjugate vaccine candidate against Streptococcus pneumoniae serotype 5
Author: Marilda P. Lisboa, Naeem Khan, Christopher Martin, Fei-Fei Xu, Katrin Reppe, Andreas Geissner, Subramanian Govindan, Martin Witzenrath, Claney L. Pereira, and Peter H. Seeberger
Journal: PNAS - Proceedings of the Natural Academy of Sciences of the United States of America , Published Date: October 2, 2017

More Publications

Basel Area Vaxxilon AG Christoph Merian-Ring 11, 4153 Reinach, Switzerland

Berlin Area (Adlershof) Vaxxilon Deutschland GmbH Magnusstraße 11, 12489 Berlin, Germany

Click here to Email us
vaxxilon